Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 1;8(2):1929-37.
eCollection 2015.

CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances

Lei Huang  1 , A-Man Xu  1 , Qiang Peng  2
Affiliations

CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances

Lei Huang et al. Int J Clin Exp Pathol. .

Abstract

Objectives: To investigate CD147 and matrix metalloproteinase-9 (MMP-9) expressions in type II/III adenocarcinoma of esophagogastric junction (AEG), and their clinicopathological significances.

Methods: Seventy-four patients clinically and pathologically diagnosed with type II/III AEG were analyzed, each undergoing radical total gastrectomy and Roux-en-Y esophagojejunostomy. The avidin streptavidin-perosidase immunohistochemistry technique was used to detect CD147 and MMP-9 in type II/III AEGs and 20 para-tumor controls, and their correlations with clinicopathological data and their reciprocal relationship were then analyzed. Kaplan-Meier survival analysis was conducted to reveal their prognostic significances. SPSS 20.0 was used for data analysis. A difference was statistically significant with P < 0.05, and very significant with P < 0.01.

Results: In type II/III AEG CD147 and MMP-9 were mainly expressed on cellular membrane of in tumor cell cytoplasm. MMP-9 expression was significantly stronger at tumor-stroma junction and front edge of invasion. Their positive rates were significantly higher in malignant tissues than para-tumor tissues (P < 0.01 for both). There existed a significant positive correlation between both expressions (P < 0.05). They were significantly more highly expressed in cancers with lymphatic metastasis (P < 0.01 for both), at TNM III/IV stages (P < 0.01 for both), and with poor differentiation grade (P < 0.05 for both). Higher CD147 and MMP-9 expression rates were correlated with inferior postsurgical survivals (P < 0.05 for both).

Conclusions: CD147 and MMP-9 could be novel biomarkers for type II/III AEG, and potentially predict tumor progression and prognosis. They are worth further investigation.

Keywords: Adenocarcinoma of esophagogastric junction; CD147; matrix metalloproteinase 9; prognosis; tumor progression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expressions of CD147 and MMP-9 in para-AEG tissue. Immunohistochemical staining showed that CD147 (A) and MMP-9 (B) were very weakly or negatively expressed in para-AEG tissues (high power field, ×400). MMP-9, matrix metalloproteinase 9; AEG, adenocarcinoma of esophagogastric junction.
Figure 2
Figure 2
Different expression levels of CD147 and MMP-9 in AEG tissues. Revealed by immunohistochemical staining in AEG tissues, weakly positive (A), moderately positive (B), and strongly positive (C) CD147 expressions were indicated by yellow or brown color in cytoplasm or on cellular membrane, and weakly positive (D), moderately positive (E), and strongly positive (F) MMP-9 expressions were illustrated by brown color in cytoplasm (high power field, × 400). MMP-9, matrix metalloproteinase 9; AEG, adenocarcinoma of esophagogastric junction.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Suh YS, Han DS, Kong SH, Lee HJ, Kim YT, Kim WH, Lee KU, Yang HK. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255:908–915. - PubMed
    1. Mine S, Sano T, Hiki N, Yamada K, Kosuga T, Nunobe S, Shigaki H, Yamaguchi T. Thoracic lymph node involvement in adenocarcinoma of the esophagogastric junction and lower esophageal squamous cell carcinoma relative to the location of the proximal end of the tumor. Ann Surg Oncol. 2014;21:1596–1601. - PubMed
    1. Hasegawa S, Yoshikawa T, Rino Y, Oshima T, Aoyama T, Hayashi T, Sato T, Yukawa N, Kameda Y, Sasaki T, Ono H, Tsuchida K, Cho H, Kunisaki C, Masuda M, Tsuburaya A. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol. 2013;20:4252–4259. - PubMed
    1. Huang L, Xu A, Li T, Han W, Wu S, Wang Y. Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances. Med Oncol. 2013;30:651. - PubMed

Publication types

MeSH terms